NCT02126969 · REGISTRY CONDITION SEARCH

A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2023-03-13

The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation treatment paradigms.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Primary Site Complete Response Rate

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Change in Quality of Life (QOL) of Patients Receiving Low Dose Fractionated Radiation Therapy With Chemotherapy.

→

outcome · POSTED

3-year Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed locally advanced head and neck cancer of squamous type stage III, IVA and IV B and select Stage II tumors of the BOT who are appropriate for potentially curative therapy with chemoradiotherapy. * Measurable disease. * ECOG performance status of 0, 1 or 2 * No prior chemotherapy for the current locally advanced SCCHN. * Age ≥18 years. * Life expectancy of greater than 3 months * Normal organ and marrow function measured within 14 days of registration as defined below: * absolute neutrophil count ≥ 1,000/mcL * platelets ≥ 100,000/mcL * total bilirubin \< institutional upper limit of normal * AST(SGOT ≤ 2.5 × institutional upper limit of normal * Alkaline phosphatase ≤ 2.5 × institutional upper limit of normal * creatinine within normal institutional limits * OR o Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, throughout the duration of active treatment and for 4 months after completion of chemotherapy and radiation. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of active study treatment, and for 4 months after completion of chemotherapy and radiation (both induction and definitive) administration. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior chemotherapy for SCCHN * Patients who are receiving any other investigational agents. * Patients with known brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Carboplatin or Docetaxel. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women * HIV-positive patients on combination antiretroviral therapy * Other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated previous Stage I or II cancer from which the patient is currently in complete remission or other cancer from which the patient has been disease-free for 3 years. * Patients with nasopharynx or salivary gland primary site * Patients with distant metastatic disease (M1c) * Patients with grade II or greater peripheral neuropathy
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Low dose fractionated radiation - 80cGy with chemotherapy
intervention Names
Radiation: Low dose fractionated radiation - 80cGy with chemotherapy
label
Chemotherapy plus Radiation Therapy
type
EXPERIMENTAL
description
Chemotherapy only
intervention Names
Drug: Docetaxel and Carboplatin AUC 6
label
Chemotherapy without Radiation
type
ACTIVE_COMPARATOR

interventions

arm Group Labels
Chemotherapy plus Radiation Therapy
description
Chemotherapy + 80 cGy of RT
name
Low dose fractionated radiation - 80cGy with chemotherapy
type
RADIATION
arm Group Labels
Chemotherapy without Radiation
description
Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
name
Docetaxel and Carboplatin AUC 6
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: SINGLE
who Masked: PARTICIPANT

primary Purpose

TREATMENT

Enrollment

count: 45
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Primary site is defined as the original, or first site that the cancer developed in the body. In this study, primary sites within the head and neck included squamous cancers of the larynx, oral cavity, oropharynx, hypopharynx.Complete response rate in patients treated with 2 cycles of induction Docetaxel and Carboplatin with low dose fractionated radiation therapy (LDFRT) will be compared to those treated with chemotherapy alone. CRR was determined Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Where possible, surgeon also evaluated primary site and provided response assessment.
measure
Primary Site Complete Response Rate
time Frame
Up to 50 days

secondary Outcomes

description
To assess overall response rate of patients to 2 cycles of induction Docetaxel and Carboplatin with or without LDFRT. Response assessment was Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, and Progressive Disease (PD): \> 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (Note: the appearance of one or more new lesions is also considered progression).
measure
Overall Response Rate
time Frame
Up to 50 days
description
Quality of Life (QOL) will be measured pre- and post-treatment using a single 5-question QOL well-being survey. The change in score will be presented independently for each subpart of the QOL survey. 1. Physical; scores range from 7-35; higher scores indicate increased well-being 2. Social/family; scores range from 7-35; higher scores indicate increased well-being 3. Emotional; scores range from 6-30; higher scores indicate increased well-being 4. Functional; scores range from 7-35; higher scores indicate increased well-being 5. Additional Concerns; scores range from 10-50; lower scores indicate increased well-being 6. FACT-G is the sum of the first 4 scores; scores range from 27-135; higher scores indicated increased well-being 7. FACT-H\&N is the sum of the first five scores; scores range from 37-185; higher scores indicated increased well-being 8. Trial Outcome Index is the sum of 1, 4 and 5; scores range from 24-120; higher scores indicated increased well-being
measure
Change in Quality of Life (QOL) of Patients Receiving Low Dose Fractionated Radiation Therapy With Chemotherapy.
time Frame
Up to 50 days (pre- and post-treatment)
description
3-year overall survival
measure
3-year Overall Survival
time Frame
From date of randomization until date of death from any cause, assessed up to 3 years

Full study description

brief Summary: The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation treatment paradigms.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-19cd71c3060add5414ee
requested nct id
NCT02126969
primary nct id
NCT02126969
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
9da3cf73bf7a7f5558e19959fc913c077719a9a05033f0455aab1333964d62fe
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-19cd71c3060add5414ee
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02126969
occurrences
context exact
NCT02126969
end
11
exact text
NCT02126969
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/73/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
03c4a5cdf6fe9a855d5e2327acfe9f880c4722b120c03b7b74ac61a5b440b051
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice